Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 3/20 | 0.41 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | CA7 | P43166 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13827071 | 0.86 | ALDH1A1 (0.52) | ALDH1A1HPGDMAPK1CYP3A4HTT | |
| SCHEMBL23120369 | 0.86 | ALDH1A1 (0.52) | ALDH1A1HPGDMAPK1CYP3A4HTT | |
| SCHEMBL10408222 | 0.84 | ALDH1A1 (0.50) | ALDH1A1HPGDMAPK1CYP3A4HTT | |
| SCHEMBL419245 | 0.83 | TDP1 (0.56) | ALDH1A1HTTMAPTTDP1NPC1 | |
| SCHEMBL27556628 | 0.82 | NNMT (0.44) | ALDH1A1HPGDMAPK1CYP3A4MAPT | |
| SCHEMBL20342786 | 0.82 | CA1 (0.52) | ALDH1A1HPGDMAPK1CYP3A4HTT | |
| SCHEMBL30069060 | 0.79 | ALDH1A1 (0.59) | ALDH1A1HTTMAPTGAATDP1 | |
| SCHEMBL1421887 | 0.79 | ALDH1A1 (0.59) | ALDH1A1HTTMAPTGAATDP1 | |
| SCHEMBL29403778 | 0.79 | TDP1 (0.52) | ALDH1A1HPGDMAPK1CYP3A4MAPT | |
| SCHEMBL69925 | 0.79 | TDP1 (0.52) | ALDH1A1HPGDMAPK1CYP3A4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324177-B2 | Triterpene compositions and methods for use thereof | RESEARCH DEVELOPMENT FOUNDATION (US) | 2012-12-04 | — | — | US | disclosed |
| US-20110294752-A1 | TRITERPENE COMPOSITIONS AND METHODS FOR USE THEREOF | RESEARCH DEVELOPMENT FOUNDATION (US) | 2011-12-01 | — | — | US | disclosed |
| US-20100189824-A1 | TRITERPENE COMPOSITIONS AND METHODS FOR USE THEREOF | ARNTZEN CHARLES J | 2010-07-29 | — | — | US | disclosed |
| US-7670632-B2 | Triterpene compositions and methods for use thereof | RESEARCH DEVELOPMENT FOUNDATION (US) | 2010-03-02 | — | — | US | disclosed |
| EP-1079824-A4 | TRITERPENE COMPOSITIONS AND METHODS FOR USE THEREOF | RES DEV FOUNDATION (US) | 2008-03-12 | — | — | EP | disclosed |
| EP-1355642-A4 | INHIBITION OF NF-(k)B BY TRITERPENE COMPOSITIONS | RES DEV FOUNDATION (US) | 2007-04-04 | — | — | EP | disclosed |
| US-20060148732-A1 | Inhibition of NF-kappaB by triterpene compositions | RESEARCH DEVELOPMENT FOUNDATION | 2006-07-06 | — | — | US | disclosed |
| US-20060073222-A1 | Triterpene compositions and methods for use thereof | ARNTZEN CHARLES J | 2006-04-06 | — | — | US | disclosed |
| US-6962720-B2 | Triterpene compositions and methods for use thereof | RESEARCH DEVELOPMENT FOUNDATION (US) | 2005-11-08 | — | — | US | disclosed |
| US-6746696-B2 | ANTITUMOR AGENTS; APOPTOSIS | RESEARCH DEVELOPMENT FOUNDATION | 2004-06-08 | — | — | US | disclosed |
| EP-1355642-A2 | INHIBITION OF NF-(k)B BY TRITERPENE COMPOSITIONS | RESEARCH DEVELOPMENT FOUNDATION (US) | 2003-10-29 | — | — | EP | disclosed |
| US-20030039705-A1 | Triterpene compositions and methods for use thereof | RESEARCH DEVELOPMENT FOUNDATION | 2003-02-27 | — | — | US | disclosed |
| US-20030031738-A1 | Triterpene compositions and methods for use thereof | RESEARCH DEVELOPMENT FOUNDATION (US) | 2003-02-13 | — | — | US | disclosed |
| US-6444233-B1 | ANTITUMOR AGENTS | RESEARCH DEVELOPMENT FOUNDATION | 2002-09-03 | — | — | US | disclosed |
| WO-2002055016-A2 | INHIBITION OF NF-λB BY TRITERPENE COMPOSITIONS | RES DEV FOUNDATION (US) | 2002-07-18 | — | — | WO | disclosed |
| EP-1079824-A1 | TRITERPENE COMPOSITIONS AND METHODS FOR USE THEREOF | RESEARCH DEVELOPMENT FOUNDATION (a Nevada corporation) (US) | 2001-03-07 | — | — | EP | disclosed |
| WO-1999059578-A1 | TRITERPENE COMPOSITIONS AND METHODS FOR USE THEREOF | RESEARCH DEVELOPMENT FOUNDATION (US) | 1999-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294752-A1 | TRITERPENE COMPOSITIONS AND METHODS FOR USE THEREOF | OSTC, ACACA, NFATC1 | ALDH1A1 2759/4885HPGD 3454/4885MAPK1 2998/4885 |
| US-20100189824-A1 | TRITERPENE COMPOSITIONS AND METHODS FOR USE THEREOF | OSTC, ACACA, NFATC1 | ALDH1A1 2759/4885HPGD 3454/4885MAPK1 2998/4885 |
| US-20030031738-A1 | Triterpene compositions and methods for use thereof | OSTC, ACACA, NFATC1 | ALDH1A1 2759/4885HPGD 3454/4885MAPK1 2998/4885 |
| US-20030039705-A1 | Triterpene compositions and methods for use thereof | BAX, CASP3, ACACA | ALDH1A1 2361/4885HPGD 3137/4885MAPK1 2061/4885 |
| US-20060148732-A1 | Inhibition of NF-kappaB by triterpene compositions | NFKBIA, NFKB2, RELA | ALDH1A1 1797/4885HPGD 197/4885MAPK1 286/4885 |
| US-20060073222-A1 | Triterpene compositions and methods for use thereof | OSTC, ACACA, NFATC1 | ALDH1A1 2759/4885HPGD 3454/4885MAPK1 2998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.